Application of schisandrin B in drug preparation

A technology of schisandrin and medicine, which is applied in the field of medicine, can solve the problems that the effect of diabetic complications has not been reported, and the direct anti-inflammatory target of schisandrin is not clear, and achieve the effect of high-efficiency treatment

Active Publication Date: 2017-10-13
WENZHOU MEDICAL UNIV +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005]Currently, the direct anti-inflammatory target of Schisandrin B is sti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of schisandrin B in drug preparation
  • Application of schisandrin B in drug preparation
  • Application of schisandrin B in drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 5

[0023] Example 1 Effect of Schizandrin B on Organ Complications in STZ-Induced Type 1 Diabetic Mice

[0024] Male C57BL / 6 mice were obtained from the Animal Experiment Center of Wenzhou Medical College. Mice were housed in a thermostated 12-12h diurnal animal room with standard rodent chow and water. Animals spend at least one week acclimating to the environment before the start of the experiment. All protocols involving the use of animals were approved by the Animal Policy and Welfare Committee of Wenzhou Medical College (approval document: 2009 / APWC / 0031). The Schizandrin B used in the experiment is a water-soluble dosage form. The pH of the solution was 7.36 and filtered through a 0.22 microporous membrane. Male C57BL / 6 mice aged 8-10 weeks were randomly divided into 6 groups: normal control group, Schisandrin B treatment group (Sch B), diabetes group (DM), diabetes group combined with Schizandrin B (20, 40 mg / kg / d two doses) treatment group, 8 rats in each group. Low...

Embodiment 2 5

[0029] Example 2 Schizandrin B can alleviate the inflammatory response of cardiomyocytes induced by HG

[0030] The in vitro anti-inflammatory activity of Schisandrin B was tested by using the method of inhibiting the release of inflammatory factors (TNF-α and IL-6) in HG-stimulated H9c2 and rat primary cardiomyocytes. The specific method is as follows: 1.2×10 ^6 H9c2 or rat primary cardiomyocytes were cultured with DMEM medium at 37°C, the medium was renewed after 24 hours, and the tested Schisandrin B (final concentration was 2.5, 5 and 10 μM) was added for pretreatment for 1 hour, and then treated with high Sugar (HG 33mM glucose) was continued to be treated for 24 hours, and the culture medium was collected to detect TNF-α and IL-6 content by ELISA method; the cells were collected to detect the total protein concentration, and the ELISA results were divided by the corresponding total protein concentration for calibration, and compared with HG The content of TNF-α and IL-6 ...

Embodiment 3 5

[0034] Example 3 Schizandrin B specifically inhibits the complexation of TLR4 and Myd88 protein in the LPS-induced inflammatory signaling pathway

[0035] In the canonical LPS-stimulated inflammatory signaling pathway, TLR4 is the main receptor of LPS. However, the combination of TLR4 and LPS requires the participation of myeloid differentiation protein 2 (MD2) to form a LPS-TLR4-MD2 complex, which further recruits downstream intracellular adapter proteins, such as: Myd88-dependent inflammatory factor transcription pathway and TRIF-dependent interferon-beta (IFN-beta) transcription pathway. Among them, the complex of MD2 and TLR4 and the recruitment of downstream adapter protein Myd88 by TLR4 are important signs of the activation of this inflammatory pathway. We used co-immunoprecipitation experiments to detect the inhibitory activity of Schizandrin B on these two protein complexes in vitro. For experimental data, see Figure 4 . Experiments showed that schisandrin B inhibi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of schisandrin B in preparation of drugs for treatment of diabetic complications. Specifically, schisandrin B reaches the effect of treatment of diabetic complications through targeted inhibition of myeloid differentiation factor 88 (MyD88) to generate the action mechanism of lowering chronic inflammation. The schisandrin B is superior to oral administration (used for preparation of powder, tablets, pills, oral liquid and capsules). Schisandrin B can effectively relieve the occurrence and development of diabetic cardiomyopathy and diabetic nephropathy, and can become a main component in drugs for treatment of diabetic complications.

Description

technical field [0001] The invention belongs to the field of medicine, in particular, the invention relates to the use of schisandrin B in preparing medicine for treating diabetic complications. In addition, the present invention also relates to the use of schisandra B in the preparation of Myd88 inhibitors with anti-inflammatory activity. Background technique [0002] As a worldwide epidemic disease, diabetes has caused serious global health problems. Diabetic patients in China account for 9.7% of the total population. Complications of diabetes can spread to all vital organs of the body, and most diabetic patients die from complications of heart, cerebrovascular or kidney. The organ complications of diabetes are caused by a combination of multiple factors, involving inflammation, RAS activation, insulin resistance, oxidative stress, endoplasmic reticulum stress, and terminal glycation products (AGEs). Recent evidence shows that inflammation is closely related to diabetic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/36A61P9/00A61P13/12A61P9/10A61P27/02
CPCA61K31/36
Inventor 王怡韩集波梁广黄伟剑徐政
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap